A once-weekly GLP-1 RA

A once-weekly GLP-1 RA

Safety profile for Ozempic®

The most frequently reported adverse reactions in clinical trials were GI disorders, including nausea, diarrhea, and vomiting.

Statistical analyses have not been conducted,
therefore comparative statistical significance is unknown

* Abdominal pain, abdominal pain upper, abdominal pain lower, gastrointestinal pain, abdominal tenderness, abdominal discomfort, epigastric discomfort.
† Lipase increased, lipase abnormal, hyperlipasemia, lipase.

GI events generally were mild or moderate in severity and of a short duration.

GI, gastrointestinal.

Contact Us

Novo Nordisk would like every healthcare practitioner to be able to obtain information as easily and quickly as possible.
If you need information about Ozempic®, please contact:

Novo Nordisk Canada Inc.
101-2476 Argentia Road
Mississauga, Ontario
L5N 6M1

Business hours are:
Monday to Friday from
8:30 a.m. to 5:00 p.m. EST

Main number:

Main fax number:
Toll-free fax number: